M. Thomas

发表

Cyclin E is the only cyclin-dependent kinase 2-associated cyclin that predicts metastasis and survival in early stage non-small cell lung cancer.

H. Koeffler, S. Diederichs, W. Berdel, 2001, Cancer research.

Tumour regression in non-small-cell lung cancer following neoadjuvant therapy. Histological assessment

K. Schulmann, M. Thomas, K. Junker, 2005, Journal of Cancer Research and Clinical Oncology.

First-line sequential high-dose VIP chemotherapy with autologous transplantation for patients with primary mediastinal nonseminomatous germ cell tumours: a prospective trial

C. Bokemeyer, L. Kanz, N. Schleucher, 2003, British Journal of Cancer.

Phase I trial of docetaxel administered by weekly infusion in patients with advanced refractory cancer.

J. Hainsworth, H. Burris, M. Thomas, 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective randomized trial of neoadjuvant chemotherapy during the ‘wait period’ following preoperative chemoradiotherapy for rectal cancer: results of the WAIT trial

M. Thomas, T. Price, P. Hewett, 2017, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

A multicenter international randomized phase III study comparing cisplatin in combination with irinotecan or etoposide in previously untreated small-cell lung cancer patients with extensive disease.

J. Soria, A. Szczesna, P. Zatloukal, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

Risk stratification of EGFR+ lung cancer diagnosed with panel-based next-generation sequencing.

M. Kriegsmann, P. Schirmacher, A. Stenzinger, 2020, Lung cancer.

Development of treatment strategies in locally advanced non-small cell lung cancer (take home messages).

W. Berdel, M. Thomas, C. Droege, 2001, Lung cancer.

Die aktuelle Therapie des asbestassoziierten malignen Pleuramesothelioms – Ein Experten-Konsensuspapier

T. Brüning, M. Metzenmacher, M. Thomas, 2021, Pneumologie.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) versus placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced nonsquamous non-small cell lung cancer (NSCLC).

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response

J. Timmer, A. Warth, H. Dienemann, 2018, Scientific Reports.

[Subgroup Analysis of the Non-interventional REASON Study: PFS and OS According to Age, Smoking History, Gender, and Histology in NSCLC Patients Treated with Gefitinib or Chemotherapy].

P. Schirmacher, M. Dietel, M. Thomas, 2016, Pneumologie.

Vandetanib versus erlotinib in patients with advanced non-small cell lung cancer (NSCLC) after failure of at least one prior cytotoxic chemotherapy: A randomized, double-blind phase III trial (ZEST).

Michael Thomas, S. Thongprasert, P. Sunpaweravong, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

p53 tumour-suppressor gene in non-small-cell lung cancer with neoadjuvant therapy

K. Müller, M. Thomas, T. Wiethege, 2000, Journal of Cancer Research and Clinical Oncology.

Carboplatin plus oral etoposide in the management of advanced, non-small cell lung cancer: preliminary results of a Vanderbilt trial.

J. Hainsworth, M. Thomas, D. Johnson, 1992, Seminars in oncology.

Preoperative combined modality therapy with paclitaxel, carboplatin, prolonged infusion 5-fluorouracil, and radiation therapy in localized esophageal cancer: preliminary results of a Minnie Pearl Cancer Research Network phase II trial.

J. Hainsworth, M. Thomas, F. Greco, 1999, The cancer journal from Scientific American.

Paclitaxel, carboplatin, and extended-schedule etoposide in the treatment of small-cell lung cancer: comparison of sequential phase II trials using different dose-intensities.

J. Hainsworth, M. Thomas, F. Greco, 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prolonged administration of oral etoposide in non-small-cell lung cancer: a phase II trial.

J. Hainsworth, M. Thomas, D. Johnson, 1992, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PLS. plenary session

C. Obasaju, C. Gridelli, L. Sequist, 2012 .

Cisplatin / etoposide (PE) followed by twice-daily chemoradiation (hfRT/CT) versus PE alone before surgery in stage III non-small cell lung cancer (NSCLC): A randomized phase III trial of the German Lung Cancer Cooperative Group (GLCCG).

C. Rübe, M. Semik, M. Thomas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Lung cancer following lung transplant: single institution 10 year experience.

J. Odell, M. Thomas, K. Landolfo, 2013, Lung cancer.

Long-Term and Low-Grade Safety Results of a Phase III Study (PARAMOUNT): Maintenance Pemetrexed Plus Best Supportive Care Versus Placebo Plus Best Supportive Care Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non e Small-Cell Lung Cancer

C. Gridelli, L. Paz-Ares, J. Pujol, 2014 .

[Prevention, diagnosis, therapy, and follow-up of lung cancer].

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

Immunotherapeutic maintenance treatment with toll-like receptor 9 agonist lefitolimod in patients with extensive-stage small-cell lung cancer: results from the exploratory, controlled, randomized, international phase II IMPULSE study

A. Navarro, R. Huber, M. Thomas, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Melanoma during fingolimod treatment for multiple sclerosis.

F. Chochon, C. Robert, M. Thomas, 2019, European journal of cancer.

[Systemic treatment of melanoma brain metastases].

J. Grob, T. Jouary, C. Lebbé, 2015, Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique.

1295PEFFICACY AND SAFETY OF CERITINIB IN PATIENTS (PTS) WITH ADVANCED ANAPLASTIC LYMPHOMA KINASE (ALK)-REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC): AN UPDATE OF ASCEND-1.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Early Tandem High-Dose Ifosfamide, Carboplatin, Etoposide Therapy with Stem Cell Rescue for Small-Cell Lung Cancer: Brief Report on the Results of a Phase-I/II Trial

H. Serve, M. Thomas, E. Oelmann, 2002, Oncology.

Prognostic factors in nonsmall cell lung cancer: insights from the German CRISP registry

G. Zaun, M. Metzenmacher, M. Thomas, 2022, European Respiratory Journal.

Biological activity of bevacizumab and erlotinib in patients with advanced hepatocellular carcinoma (HCC).

J. Abbruzzese, M. Thomas, E. Garrett-Mayer, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients.

M. Thomas, C. Robert, L. Lacroix, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Tumour cell proliferation (Ki-67) in non-small cell lung cancer: a critical reappraisal of its prognostic role

H Dienemann, A. Warth, H. Dienemann, 2014, British Journal of Cancer.

Optimizing panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, P. Schirmacher, A. Stenzinger, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Ploidy, expression of erbB1, erbB2, P53 and amplification of erbB1, erbB2 and erbB3 in non-small cell lung cancer.

N. Reinmuth, H. Scheld, M. Semik, 2000, The European respiratory journal.

A randomized, open-label, multicenter, phase II study evaluating the efficacy and safety of BTH1677 (1,3–1,6 beta glucan; Imprime PGG) in combination with cetuximab and chemotherapy in patients with advanced non-small cell lung cancer

J. Marier, F. Schneller, M. Thomas, 2017, Investigational New Drugs.

Association of the advanced lung cancer inflammation index (ALI) with immune checkpoint inhibitor efficacy in patients with advanced non-small-cell lung cancer

M. Kriegsmann, A. Stenzinger, K. Samitas, 2021, ESMO open.

Everolimus with paclitaxel and carboplatin as first-line treatment for metastatic large-cell neuroendocrine lung carcinoma: a multicenter phase II trial

C. Kropf-Sanchen, P. Schnabel, W. Engel-Riedel, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Current data on predictive markers for anti-angiogenic therapy in thoracic tumours

N. Reinmuth, M. Kreuter, P. Schnabel, 2010, European Respiratory Journal.

[New strategies for NSCLC: is inhibition of tumour vasculature useful].

N. Reinmuth, M. Kreuter, M. Thomas, 2010, Pneumologie.

One-hour paclitaxel plus carboplatin in the treatment of advanced non-small cell lung cancer: results of a multicentre, phase II trial.

J. Hainsworth, W. Urba, M. Thomas, 1998, European journal of cancer.

Identification of a highly lethal V3+TP53+ subset in ALK+ lung adenocarcinoma

P. Schirmacher, A. Stenzinger, R. Penzel, 2018, International journal of cancer.

Clinical management patterns and treatment outcomes in patients with non-small cell lung cancer (NSCLC) across Europe: EPICLIN-Lung study

A. Carrato, M. Thomas, A. Vergnenègre, 2014, Current medical research and opinion.

Improved diagnostics targeting c-MET in non-small cell lung cancer: expression, amplification and activation?

A. Warth, K. Rabe, T. Goldmann, 2015, Diagnostic Pathology.

Expression ratio of the TGFβ-inducible gene MYO10 is prognostic for overall survival of squamous cell lung cancer patients and predicts chemotherapy response

J. Timmer, A. Warth, H. Dienemann, 2018, Scientific Reports.

Prognostic relevance of angiogenesis in stage III NSCLC receiving multimodality treatment

N. Reinmuth, J. Gerss, M. Kreuter, 2009, European Respiratory Journal.

Optimizing panel-based tumor mutational burden (TMB) measurement.

S. Fröhling, P. Schirmacher, A. Stenzinger, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

One-hour paclitaxel infusions: review of safety and efficacy.

J. Hainsworth, M. Thomas, F. Greco, 1999, The cancer journal from Scientific American.

Randomized phase 2 trial on refinement of early-stage NSCLC adjuvant chemotherapy with cisplatin and pemetrexed versus cisplatin and vinorelbine: the TREAT study.

C. Schumann, I. Zuna, M. Kreuter, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

Anti-MEK Agents in Perspective

C. Robert, P. Robins, M. Thomas, 2013 .

Messenger RNA vaccination in NSCLC: Findings from a phase I/IIa clinical trial.

D. Atanackovic, R. Bals, F. Mayer, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A blood-based miRNA signature predicts immunotherapy efficacy in advanced stage non-small cell lung cancer

K. Rabe, R. Horos, T. Sauka-Spengler, 2021, medRxiv.

Systemic therapy treatment patterns in patients with advanced non‐small cell lung cancer (NSCLC): PIvOTAL study

P. Tagliaferri, Dae-Ho Lee, M. Thomas, 2017, European journal of cancer care.

Prevention, Diagnosis, Therapy, and Follow-up of Lung Cancer

H. Kauczor, I. Petersen, C. Rübe, 2010, Pneumologie.

Trimodality therapy in stage III non-small cell lung cancer: prediction of recurrence by assessment of p185neu.

N. Willich, C. Rübe, H. Scheld, 1999, The European respiratory journal.

Open, randomized, multi-center phase II study comparing efficacy and tolerability of Erlotinib vs. Carboplatin/Vinorelbin in elderly patients (>70 years of age) with untreated non-small cell lung cancer.

Michael Thomas, P. Schnabel, C. Kortsik, 2014, Lung cancer.

Paclitaxel, carboplatin, and extended-schedule oral etoposide for small-cell lung cancer.

J. Hainsworth, M. Thomas, F. Greco, 1998, Oncology.

Grading of tumor regression in non-small cell lung cancer : morphology and prognosis.

M. Thomas, K. Junker, F. Klinke, 2001, Chest.

Therapy of localized non-small cell lung cancer (take home messages).

M. Baumann, M. Thomas, G. Stamatis, 2001, Lung Cancer.

Efficacy and safety of maintenance pemetrexed in patients with advanced nonsquamous non-small cell lung cancer following pemetrexed plus cisplatin induction treatment: A cross-trial comparison of two phase III trials.

G. Scagliotti, C. Gridelli, F. de Marinis, 2014, Lung cancer.

The immune microenvironment in EGFR- and ERBB2-mutated lung adenocarcinoma

S. Fröhling, M. Kriegsmann, P. Schirmacher, 2021, ESMO open.

Induction treatment before surgery for non-small cell lung cancer.

R. Mirimanoff, J. Pignon, A. Gregor, 2003, Lung cancer.

Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer.

N. Willich, C. Rübe, H. Scheld, 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Effect of timing, technique and molecular features on brain control with local therapies in oncogene-driven lung cancer

J. Debus, A. Stenzinger, D. Kazdal, 2021, ESMO open.

Paclitaxel, carboplatin, and vinorelbine in the treatment of advanced non-small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network.

J. Hainsworth, H. Burris, M. Thomas, 2000, Cancer journal.

C. Gridelli, F. de Marinis, L. Paz-Ares, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Sequential photodynamic therapy (PDT) and high dose brachytherapy for endobronchial tumour control in patients with limited bronchogenic carcinoma

L. Freitag, M. Thomas, R. Prenzel, 2004, Thorax.

Real-world healthcare resource utilization in a European non-small cell lung cancer population: the EPICLIN-Lung study

A. Carrato, M. Thomas, A. Vergnenègre, 2014, Current medical research and opinion.

A systemic description of small cell lung carcinoma, alternative theoretical proposals and clinical implications

J. Salomon, M. Thomas, 1988 .

Treatment of non-small cell lung cancer with intensity-modulated radiation therapy in combination with cetuximab: the NEAR protocol (NCT00115518)

S. Nill, U. Haberkorn, J. Debus, 2006, BMC Cancer.

[Prevention, diagnosis, therapy, and follow-up of lung cancer. Interdisciplinary guideline of the German Respiratory Society and the German Cancer Society--abridged version].

H. Kauczor, I. Petersen, C. Rübe, 2011, Pneumologie.

Single agent gefitinib in poor performance status patients with previously untreated advanced non-small cell lung cancer: A Minnie Pearl Cancer Research Network phase II trial.

J. Hainsworth, H. Burris, M. Thomas, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[Regression grading of neoadjuvant non-small-cell lung carcinoma treatment].

K. Schulmann, M. Thomas, K. Junker, 1997, Der Pathologe.

Bevacizumab and erlotinib in the treatment of patients (pts) with metastatic carcinoma of unknown primary site: A Sarah Cannon Research Institute phase II trial

J. Hainsworth, M. Thomas, D. Spigel, 2005 .

Biomarker study evaluating the combination of dabrafenib (D) with trametinib (T) versus the combination after 8 weeks of monotherapy with dabrafenib or trametinib in patients with metastatic and unresectable stage IIIC or IV melanoma: GSK study 116613.

C. Robert, M. Thomas, S. Vagner, 2014 .

1293PEVALUATION OF CERITINIB-TREATED PATIENTS (PTS) WITH ANAPLASTIC LYMPHOMA KINASE REARRANGED (ALK+) NON-SMALL CELL LUNG CANCER (NSCLC) AND BRAIN METASTASES IN THE ASCEND-1 STUDY.

A. Shaw, Gregory Riely, E. Felip, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.